Lethality of sepsis is over 20% in children [6] and [7]. Prevention is therefore a priority. Thirteen different serotypes

are known, but, as known, most invasive meningococcal disease is caused by one of six capsular groups A, B, C, W135, X and Y. Excellent conjugate vaccines have been licensed so far. In Italy, since the introduction of conjugate meningococcal C vaccine (MenC), a rapid and sustained reduction in the incidence of invasive MenC disease across all age groups occurred [8] and [9]. As a consequence, capsular group B (MenB) has become responsible for most cases [7] and [9]. A vaccine against group Regorafenib mw B has recently been licensed in Europe and other vaccines are under study; preliminary data regarding immunogenicity and safety are promising both in infants and adolescents or adults [10] and [11]. With the aim to provide broader cross-protection, vaccines under development include highly conserved subcapsular proteins such as PorA, variants of factor H binding protein (fHbp), Neisserial Heparin binding Antigen (NHBA) and Neisserial adhesin A (NadA) [1]. In order to plan an effective vaccination schedule, it is important to know when the greatest burden of meningococcal B disease occurs and if vaccine prevention should be done during the http://www.selleckchem.com/products/Fulvestrant.html first year of life or later. The aim of the present study is therefore to describe the epidemiology of

invasive meningococcal B disease across pediatric

age groups so to define the optimal age for vaccination. This observational, retrospective, cohort study was designed to evaluate the distribution of meningococcal B invasive disease cases across age groups in children admitted with a clinical suspicion of community-acquired meningitis or sepsis to Pediatric Hospitals or Pediatric wards of general hospitals in Italy from December 2006 to December 2012. This study was a part of a prospective study aimed at obtaining epidemiological and clinical data of Italian children with invasive bacterial diseases [12]. Hospitals L-NAME HCl from all Italian regions were invited to participate (see Table A, provided as supplementary file, for the characteristic of the participating hospitals). Bacterial meningitis was suspected in the presence of at least two of the following clinical signs: bulging fontanelle, drowsiness or irritability, opisthotonus, neck stiffness, vomit or seizures [13] A bacterial meningitis case was defined when clinical signs were associated to the positivity of RT-PCR (Realtime Polymerase Chain Reaction) and/or blood or CSF (Cerebral Spinal Fluid) culture for a bacterium. Meningococcal meningitis was defined by the presence of clinical suspicion together with chemical CSF tests and the positivity of culture or RT-PCR on CSF for N. meningitidis. Meningococcal meningitis was defined associated to sepsis when RT-PCR was positive for N.